BioNTech Puts $200M Into Collab With Cancer Biotech Autolus
By Yeji Jesse Lee · February 8, 2024, 9:58 PM EST
German immunotherapy company BioNTech will inject $200 million into cancer-focused biotechnology firm Autolus Therapeutics PLC as part of a strategic collaboration announced Thursday....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login